XERIS BIOPHARMA HOLDINGS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $985.00K, a 18.67% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $830.00K, a 16.90% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $710.00K, a 29.33% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $549.00K, a 7.65% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.52M, a 22.19% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.24M, a 126.59% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $549.00K, a 33.70% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $828.00K, a 28.97% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $985.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $1.52M 10-K · filed 2026-03-02 | |
| 2025-06-30 | $830.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.24M 10-K · filed 2026-03-02 | |
| 2024-06-30 | $710.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $549.00K 10-K · filed 2026-03-02 | |
| 2023-06-30 | $549.00K 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $828.00K 10-K · filed 2025-03-06 | |
| 2022-06-30 | $510.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $642.00K 10-K · filed 2024-03-06 | |
| 2021-06-30 | $374.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $669.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $2.05M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $385.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |